Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicola Farina

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
European Journal of Internal Medicine|May 27, 2026
Beyond categorical exclusion: Reclaiming clinical judgment in the use of JAK inhibitors for rheumatoid arthritisNicola Farina, Lorenzo Dagna
European Journal of Internal Medicine|May 1, 2022
Interleukin 6 inhibition in severe COVID-19: Another piece of the puzzleNicola Farina, Lorenzo Dagna
European Journal of Internal Medicine|August 4, 2023
Immune regulators for the treatment of COVID-19: A critical appraisal after two yearsNicola Farina, Lorenzo Dagna
Clinical Rheumatology|February 5, 2020
Obesity and its role in the management of rheumatoid and psoriatic arthritisLuca Moroni, Nicola Farina, Lorenzo Dagna
European Journal of Internal Medicine|December 10, 2024
Redefining giant cell arteritis: From current practices to future paradigmsAlessandro Tomelleri, Nicola Farina, Lorenzo Dagna
European Journal of Internal Medicine|November 7, 2022
Giant cell arteritis: Update on clinical manifestations, diagnosis, and managementNicola Farina, Alessandro Tomelleri, Corrado Campochiaro, et al.
Expert Opinion on Drug Safety|October 20, 2020
Current treatment options and safety considerations when treating adult-onset Still's diseaseGiulio Cavalli, Nicola Farina, Corrado Campochiaro, et al.
Rheumatology (Oxford, England)|March 17, 2023
Adult-onset Still's disease complicated by Guillain-Barré syndromeNicola Farina, Daniel Arroyo-Sánchez, Corrado Campochiaro, et al.
Clinical and Experimental Rheumatology|March 29, 2022
Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's diseaseCorrado Campochiaro, Nicola Farina, Alessandro Tomelleri, et al.
Annals of the Rheumatic Diseases|December 11, 2019
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester diseaseCorrado Campochiaro, Giulio Cavalli, Nicola Farina, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
European Journal of Internal Medicine|May 27, 2026
Beyond categorical exclusion: Reclaiming clinical judgment in the use of JAK inhibitors for rheumatoid arthritisNicola Farina, Lorenzo Dagna
European Journal of Internal Medicine|May 1, 2022
Interleukin 6 inhibition in severe COVID-19: Another piece of the puzzleNicola Farina, Lorenzo Dagna
European Journal of Internal Medicine|August 4, 2023
Immune regulators for the treatment of COVID-19: A critical appraisal after two yearsNicola Farina, Lorenzo Dagna
Clinical Rheumatology|February 5, 2020
Obesity and its role in the management of rheumatoid and psoriatic arthritisLuca Moroni, Nicola Farina, Lorenzo Dagna
European Journal of Internal Medicine|December 10, 2024
Redefining giant cell arteritis: From current practices to future paradigmsAlessandro Tomelleri, Nicola Farina, Lorenzo Dagna
European Journal of Internal Medicine|November 7, 2022
Giant cell arteritis: Update on clinical manifestations, diagnosis, and managementNicola Farina, Alessandro Tomelleri, Corrado Campochiaro, et al.
Expert Opinion on Drug Safety|October 20, 2020
Current treatment options and safety considerations when treating adult-onset Still's diseaseGiulio Cavalli, Nicola Farina, Corrado Campochiaro, et al.
Rheumatology (Oxford, England)|March 17, 2023
Adult-onset Still's disease complicated by Guillain-Barré syndromeNicola Farina, Daniel Arroyo-Sánchez, Corrado Campochiaro, et al.
Clinical and Experimental Rheumatology|March 29, 2022
Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's diseaseCorrado Campochiaro, Nicola Farina, Alessandro Tomelleri, et al.
Annals of the Rheumatic Diseases|December 11, 2019
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester diseaseCorrado Campochiaro, Giulio Cavalli, Nicola Farina, et al.
Pageof 5